A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A
Study sponsor: Vir Biotechnology, Inc. · VIR
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-05-05Actual
Enrollment · participants2977Actual
Source updated2024-09-19Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.